title: MHH-CALL4_Ruxo_1
description: Protocols: Cells treated with drugs for 24hr were collected Cells were grown is RPMI1640-10%FCS media. Cells were treated with either ruxolitinib (JAK1/2 inhibitor), FX1(BCL6 inhibitor), their combination, or DMSO(control) for 24 hrs. Qiagen RNAeasy-plus mRNA enriched using oligo(dT) beads was fragmented randomly by adding fragmentation buffer, then the cDNA is synthesized by using mRNA template and random hexamers primer, after which a custom second-strand synthesis buffer (Illumina) , dNTPs, RNase H and DNA polymerase I are added to initiate the second-strand synthesis. Second, after a series of terminal repair, A ligation and sequencing adaptor ligation, the double-stranded cDNA library is completed through size selection and PCR enrichment.
attributes.tag: ENA first public
attributes.value: 2022-03-31
attributes.tag: ENA last update
attributes.value: 2022-03-31
attributes.tag: External Id
attributes.value: SAMEA9434927
attributes.tag: INSDC center alias
attributes.value: Aichi Medical University
attributes.tag: INSDC center name
attributes.value: Aichi Medical University
attributes.tag: INSDC first public
attributes.value: 2022-03-31T00:17:20Z
attributes.tag: INSDC last update
attributes.value: 2022-03-31T00:17:20Z
attributes.tag: INSDC status
attributes.value: public
attributes.tag: Submitter Id
attributes.value: E-MTAB-10755:MHH-CALL4_Ruxo_1
attributes.tag: broker name
attributes.value: ArrayExpress
attributes.tag: cell line
attributes.value: MHH-CALL-4
attributes.tag: cell type
attributes.value: precursor B cell
attributes.tag: common name
attributes.value: human
attributes.tag: developmental stage
attributes.value: juvenile stage
attributes.tag: disease
attributes.value: precursor lymphoblastic lymphoma/leukemia
attributes.tag: genotype
attributes.value: IGH@-CRLF2
attributes.tag: organism part
attributes.value: peripheral blood
attributes.tag: sample name
attributes.value: E-MTAB-10755:MHH-CALL4_Ruxo_1